Acuity Strategic Partners

Executive Summary

Acuity Strategic Partners is a Boston-based boutique life sciences consultancy that provides integrated commercial, advocacy, government affairs, and communications strategies to emerging life science companies, with a focus on rare diseases and specialty therapeutics. Founded in 2014, the firm has positioned itself as a critical partner for companies navigating the complex launch and market access landscape. By offering end-to-end support—from launch preparation and market access to patient advocacy and legislative lobbying—Acuity helps clients accelerate market adoption and overcome regulatory hurdles. With a lean team of 11–50 employees, the firm's deep expertise in rare diseases allows it to command a niche in the high-stakes specialty therapy market. As the life sciences industry increasingly pivots toward precision medicine and orphan drug development, Acuity's specialized advisory services are well-aligned with sector growth trends. The company's private status and lack of disclosed funding suggest it operates on a cash-flow-positive model, generating revenue through client engagements. While not a drug developer itself, Acuity's success is tied to the progress of its client portfolio, making it a bellwether for emerging biotech commercialization challenges.

Upcoming Catalysts (preview)

• Q3 2026Landmark client drug approval (e.g., rare disease therapy) driving revenue milestone75% success
• Q3 2026Announcement of strategic partnership or expansion into new therapeutic area (e.g., oncology or gene therapy)60% success
• TBDKey senior hire (e.g., VP of Market Access or Head of Patient Advocacy) to strengthen service offerings80% success